VBI 2601
Alternative Names: BRII-179; VBI-2601Latest Information Update: 28 Mar 2024
At a glance
- Originator VBI Vaccines
- Developer Brii Biosciences; VBI Vaccines
- Class Antivirals; Hepatitis B vaccines; Immunotherapies; Protein vaccines; Recombinant proteins; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 22 Mar 2024 Brii Biosciences plans a pivotal clinical trial for Hepatitis B (Combination therapy) in China (IM), in the second half of 2024
- 14 Feb 2024 Brii Biosciences and VBI Vaccines enter into an agreement for expansion and control of clinical and commercial supplies of VBI 2601 for Hepatitis B
- 30 Nov 2023 VBI 2601 receives Breakthrough Therapy status for Hepatitis B in China